1. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials;Clotet;Lancet,2007
2. El-Sadr W, for the SMART Study Group. Inferior clinical outcomes with episodic CD4-guided antiretroviral therapy aimed at drug conservation (DC) in SMART study: consistency of finding in all patient subgroups. Toronto: 16th International AIDS Congress, 2006 (abstr WEAB0204).
3. DeJesus E, LaMarca A, Sension M, Beltran C, Yeni P. The CONTEXT study: efficacy and safety of GW433908/r in PI-experienced subjects with virological failure (24 week results). Boston: 10th Conference on Retroviruses and Opportunistic Infections, 2003 (abstr 178).
4. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures;Johnson;AIDS,2005
5. Pollard RB, Thompson MA, Hicks CB, et al. Phase 3 comparison of lopinavir/ritonavir vs investigator-selected protease inhibitors in single PI-experienced, NNRTI-naive patients: 48-week results of study M98-888. Glasgow: Proceedings of the 7th International Congress on Drug Therapy in HIV Infection, 2004 (abstr PL3.2).